Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Diamyd® in combination with etanercept and vitamin D shows safety after six months

Diamyd Medical today announced that a first six-month interim report from EDCR IIa, a clinical researcher-initiated pilot trial in which the diabetes vaccine Diamyd® is combined with the immunosuppressive drug etanercept and vitamin D, when all 20 patients have been followed for six months, preliminary shows that the treatment is safe and tolerable. No serious side effects have been reported. Professor Johnny Ludvigsson, principal investigator and sponsor for the study will present the 6-month-results tomorrow Saturday, May 20, at the Scandinavian Society for the Study of Diabetes meeting

Veidekke ASA: Shares to senior executives 2017

1,067 senior executives in Veidekke have received offers to purchase between 50 and 2,000 Veidekke shares each. The senior executives could choose between two alternatives: Option A with 20 % discount and partial financing (1,000 - 2,000 shares) and option B with 30 % discount and no financing (50 - 2,000 shares). 643 senior executives subscribed for a total of 832,855 shares during the subscription period from 11 to 18 May. The offer prices were NOK 89.26 (option A) and NOK 78.10 (option B) after the 20 % / 30 % discount on the market price during the subscription period. The lock-in

Kurekss first in the Baltic region with TC continuous kiln

The Latvian sawmill Kurekss has invested in a TC continuous kiln from Valutec. This will be the first continuous kiln of this model to be built in the Baltic countries.“Kurekss has clear ideas for how they want to develop their business. At the same time, they are open to innovative thinking, and when we presented the TC continuous kiln, they quickly realised that it was ideally suited to meet their specific needs,” comments Stefan Sundqvist, Export Sales Manager at Valutec.Kurrekss is a privately-owned sawmill in western Latvia that was founded in 1995. A large part of the company’s

STAR ALLIANCE LAUNCHES 20TH ANNIVERSARY MILEAGE COMPETITION

Share your favourite cultural experience for a chance to become a mileage millionaire* To celebrate 20 years of connecting people and cultures, Star Alliance and its 28 member carriers today announced the launch of a worldwide competition whereby customers can share their favourite cultural experiences with other travellers for a chance to win a million frequent flyer miles* from their selected Star Alliance Frequent Flyer Programme (FFP). All 21 Star Alliance FFPs are participating in the competition, which starts on May 14th and ends on July 31st, 2017. “Each year, for 20

Rovaniemi is by nature the Arctic Design Capital

With the temperature well below zero, the landscape covered with snow, and the night sky lit up with the Aurora Borealis, Rovaniemi is the perfect platform for Arctic design.What is ‘Arctic design’ and why is Rovaniemi called the Arctic Design Capital? ‘The Arctic design perspective combines the demands of Arctic conditions, top research and training in the field, creative industry expertise, and Northern culture,” says Tuula Rintala-Gardin from the city of Rovaniemi. Arctic know-how draws on traditional materials in Rovaniemi. “In addition to spectacular snow and ice constructions, we

Lewek Connector: Extension of charter contract

Reference is made to the stock exchange release from Ocean Yield ASA (“Ocean Yield”) dated 16 February 2017, regarding a 4 months’ bareboat charter contract for the Lewek Connector to a related company of Ezra Holdings Ltd. at a rate of USD 40,000 per day (the “Charter”). Connector 1 AS (a wholly owned subsidiary of Ocean Yield) has now entered into a contract for extension of the Charter for a firm period of 3 months’, plus further extensions in charterers option for a period of up to 2 months, at a rate of USD 40,000 per day. The extended Charter period commences on 1 June 2017.

Change in number of shares in Brighter AB.

Conversion of convertible notes into shares under the Convertible Notes issued under the financing agreement announced on April 26. The number of Notes converted on May 15 2017 was 25. The number of Notes remaining under the first Tranche for future conversion is 260. The number of shares and the number of votes before the conversion was 52,410,170. Through the conversion, the number of shares and the number of votes have increased by 666,666. The total number of shares and the total number of votes after the conversion amount to 53,076,836. For terms and conditions of the Notes,

Wilson Therapeutics to present at Bioequity Europe

Jonas Hansson, Chief Executive Officer, will present Wilson Therapeutics at the 18thannual Bioequity Europe investor conference that will be held May 22-23, 2017 in Paris, France. The presentation will be held at 14:20 CET on May 23 at the conference venue Marriott Rive Gauche in Paris.About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been

FIRST DAY OF TRADING IN THE MUNTERS SHARE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION NOTICE AT THE END OF THE PRESS RELEASE.For the complete press release follow this link: https://www.munters.com/en/media/news/global-news/2017/nasdaq/ For more information: John Peter Leesi, CEO Munters GroupPhone: +46 8 626 63 60 John Womack, Investor RelationsPhone: +46 706 782499 THIS

ElectriCity partnership wins UITP Awards 2017

The ElectriCity partnership for electrified transportation in Gothenburg, Sweden, took first prize in the "operational and technical excellence" category when the prestigious UITP Awards 2017 competition results were announced in Montreal on May 17th.The award was received by Volvo Buses and Västtrafik, two of the main partners in ElectriCity. The partnership’s most public aspect is bus route 55, where 10 electrified Volvo buses have been plying the route between the two Chalmers University of Technology campuses since 2015. So far more than 1.5 million passengers have used route 55. The

Interim report January - March 2017

·  Net sales amounted to MSEK 0 (0). ·  The operating loss for the reporting period was -3,2 (-2,9) MSEK  ·  Net loss was 3,3 (-3,1) MSEK, corresponding to a loss per share of SEK 3,65 (3,57)  ·  Cash flow from operating activities amounted to -2,8 (-7,2) MSEK ·  Cash and cash equivalents amounted to 3,8 (9,1) MSEK Significant events during the period January - March ·  A co-operation agreement was signed with the American biotech company Cellastra Inc. regarding the clinical development of PXL01 in North America ·  The company formally changed name from Lipopeptide

STABILISATION NOTICE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION NOTICE AT THE END OF THE PRESS RELEASE.Munters Group AB For the complete press release follow this link: https://www.munters.com/en/media/news/global-news/2017/pre-stabilisation-notice/ This information was released for publication at 08:00 CET on 19 May 2017.

Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017

Bergen, Norway, May, 19 2017 – Leading oncology biopharmaceutical company BerGenBio ASA, announces that its first-in-class small molecule Axl inhibitor BGB324 will be featured in a poster presentation at the upcoming 2017 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL from June 2-6, 2017. The presentation will focus on pre-clinical as well as clinical activity of BGB324 in high-risk Myeloid Dysplastic Syndrome (MDS).The details of the poster presentation are as follows: Blockade of Axl with the small molecule inhibitor BGB324 shows activity in vitro and in

CHANGE IN WULFF GROUP PLC’S EXECUTIVE BOARD

STOCK EXCHANGE RELEASE         May 19, 2017 at 9.00 A.M.  Wulff Group Plc’s CFO and Group Executive Board member Elina Rahkonen resigns from her position and transfers to another company at the beginning of August 2017. The search for a new CFO will begin immediately.  Wulff Group Plc’s CEO and Chairman of the Group Executive Board Kimmo Laaksonen, CEO of Wulff Entre Ltd Ninni Arion, Managing Director of Wulff Supplies Ab Trond Fikseaunet, Wulff Group Plc’s Communications and Marketing Director Tarja Törmänen, and Veijo Ågerfalk, Head of Direct Sales Division, will continue in the

TECHSTEP APPOINTS INGE PAULSEN AS COO

Techstep continues to grow and strengthens its corporate management team by appointing Inge Paulsen as the company’s Chief Operating Officer (COO). During the last six months, Techstep has made several acquisitions to establish itself as a leading enabler of the digital workplace in the Nordics. By combining our existing business with the new acquisitions, we have increased our end-user base from 220,000 to 450,000. Now we must focus on integrating the companies and bring out synergies to offer a complete solution for making the work life mobile for our customers. Inge brings with him

Orkla expands in personal care

Orkla Care has signed and closed an agreement to purchase 100% of the shares in the Danish company Riemann Holding A/S ("Riemann"). The company holds good positions in the sun protection and antiperspirant markets, and with the acquisition of Riemann, Orkla Care is strengthening its presence in the pharmacy channel.   The product portfolio is marketed under the P20 and Perspirex brands and is primarily sold through the pharmacy channel via distributors. Riemann is based in Denmark, but around 90% of its turnover is generated by exports to other European markets. The business has achieved

Interim report January 1 - March 31, 2017

RaySearch Laboratories AB (publ) “The positive trend continued in the first quarter and net sales increased 33 percent to SEK 127 M (95), of which revenues from RayStation® rose 39 percent to SEK 112 M (81), and operating profit rose 43 percent to SEK 33 M (23). MD Anderson has become collaboration partner regarding RayCare® and the development work is progressing as planned,” says Johan Löf, President and CEO of RaySearch.  THREE MONTHS (JANUARY-MARCH 2017)  · Net sales SEK 126.8 M (95.4), of which revenues from RayStation SEK 112.3 M (80.8)  · Profit after tax SEK 26.3 M (17.

CLX Communications AB (publ): new financial targets

Stockholm, Sweden - CLX Communications AB (publ) - XSTO: CLX - announces that the Board of CLX Communications AB (publ) have decided to set new financial targets for the business. The new financial targets are: · Growth in adjusted EBITDA per share shall be 20 per cent per year, starting with calendar year 2016. · CLX target is that net debt over time shall be below two times adjusted EBITDA (measured on rolling twelve months). · Dividend policy - the Board continues to see good growth opportunities through acquisitions over the next few years, and therefore proposes that

CLX Communications AB (publ): Strong profit trend creating scope for continued growt

Interim report, January - March 2017 First quarter, January - March 2017 · Net sales increased by 133 percent to SEK 622.2 million (267.2). Organic growth was 20 percent. · EBITDA amounted to SEK 70.8 million (25.3). · EBITDA excluding items affecting comparability[1] (adjusted EBITDA) amounted to SEK 80.9 million (25.3). · EBIT amounted to SEK 41.1 million (23.6). · Net profit for the quarter amounted to SEK 33.4 million (18.4). · Basic and diluted earnings per share amounted to SEK 0.67 (0.49). Significant events during the quarter · Under the

BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

Stockholm, Sweden – 18 May 2017 — Oncopeptides AB’s (ONCO) annual general meeting 2017 was held today, at IVA Conference center in Stockholm. At the meeting, the following principal resolutions were passed.·  The presented annual report was adopted and the members of the Board of Directors and the CEO were discharged from liability in respect of the financial year 2016. ·  It was resolved to carry forward the loss for the year in accordance with the Board of Directors’ proposal. ·  The proposed remunerations to the Board of Directors, its committees and the Company’s auditor were

Ericsson and Landmark to build intelligent IoT microgrid

· Ericsson has been selected by Landmark to build communications infrastructure for its intelligent microgrid ecosystem across North America · The program includes Ericsson's Zero Site communications platform, cloud, core and IoT software solutions · Ericsson will provide microgrid management, integrating communications for the industrial IoT with battery storage applications and grid-control software Ericsson (NASDAQ: ERIC) has been chosen by leading real estate and infrastructure firm Landmark Dividend LLC, the sponsor of Landmark Infrastructure Partners LP (NASDAQ: LMRK), to

Deflamo AB: Pressrelease from Annual General Meeting 2017

This release is only published in Swedish.  Malmö 2017-05-18 Vid årsstämman i Deflamo AB (publ) ("Bolaget") den 18 maj 2017 beslutades följande:  Resultat- och balansräkning, vinstdisposition, ansvarsfrihetStämman beslutade att fastställa den framlagda resultat- och balansräkningen, att ingen vinstutdelning ska ske för räkenskapsåret 2016 samt att ansvarsfrihet lämnas åt verkställande direktören och styrelsens ledamöter.  Styrelse, revisorer och arvoden Stämman beslutade att styrelsen ska bestå av fem ordinarie ledamöter utan suppleanter. Eric Appelman, Jan Blomquist, Åsa

There are no items matching the current filter
There are no more items matching the current filter
Back to top